News & Publications Press Releases September 04, 2025 Pulmovant receives orphan drug designation in Japan for Mosliciguat for the treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)June 16, 2025 Pulmovant announces publication of Pharmacokinetics and Lung Deposition Data for Inhaled Mosliciguat in Clinical PharmacokineticsSeptember 10, 2024 Pulmovant presents positive proof-of-concept data from the Phase 1b ATMOS study of Mosliciguat in Pulmonary Hypertension at European Respiratory Society Congress Publications May 22, 2025Clinical Pharmacokinetics: Pharmacokinetics and Lung Deposition Data for Inhaled MosliciguatMay 19, 20252025 American Thoracic Society Congress Presentation - ATMOS, a Proof-of-Concept Trial of Inhaled Mosliciguat in Untreated PAH or CTEPHMay 18, 20252025 American Thoracic Society Congress Poster - Characterizing Subgroup Variability within WHO Group 3 Pulmonary Hypertension with Real World Evidence September 10, 20242024 European Respiratory Society Congress Poster - ATMOS, a Proof-of-Concept Trial of Inhaled Mosliciguat in Untreated PAH or CTEPH
